On this page

Begin with the goal

The decision is broader than stopping a visible twitch. It can include making reading or work easier, reducing embarrassment, avoiding a treatment burden or seeking lasting spasm freedom. Discuss which changes would matter most and how they will be assessed. Suitability for any intervention depends on clinical evaluation.

Botulinum toxin: symptom control

Toxin injections act on affected muscles to reduce their activity temporarily. The Movement Disorder Society describes benefit averaging about three months, with individual variation and repeated treatment. This approach does not surgically remove an offending vessel-nerve relationship. Local effects can include eyelid drooping, eye symptoms or weakness around the mouth.1

Repeated appointments can be an acceptable long-term plan for some people and burdensome for others. Discuss the benefit achieved across a treatment cycle, including the period when symptoms return, rather than judging only the best day after treatment.

MVD: a different intervention

Microvascular decompression aims to relieve relevant vascular compression of the facial nerve in suitable patients. It offers the possibility of durable spasm freedom but involves an intracranial operation and recovery. Hearing loss, facial weakness and cerebrospinal-fluid leakage are among reported complications. Published surgical cohorts are useful context; they cannot guarantee one person's result.23

Medicines and other approaches

Oral medicines are sometimes tried, especially when injections or surgery are unsuitable or unwanted. The 2025 update describes limited evidence and benefit, with possible sleepiness, dizziness and weakness. It also discusses emerging approaches whose durability and safety need better study.2

Why percentages do not decide the comparison

Cochrane found no eligible parallel toxin-versus-placebo trials under its 2020 criteria, while acknowledging observational improvement. The later 2024 review includes predominantly uncontrolled studies and randomized comparisons of added lower-face treatment, with active eye-area treatment in both arms. This is different evidence from surgical spasm-freedom series.45

A percentage describing symptom improvement after an injection cannot be compared directly with spasm freedom at a surgical follow-up as if the same patients were randomized between them. Neither result measures every important outcome, and the studies have different biases.

Making the discussion practical

Ask about the expected goal, the likely follow-up plan, relevant risks, alternatives and what happens if relief is incomplete. For surgery, ask for the team's own clearly defined outcomes and complication experience. For toxin, discuss response and unwanted effects over repeated cycles. A fair choice makes these trade-offs explicit without assuming that every person should favor the same treatment.

References

  1. International Parkinson and Movement Disorder Society. Hemifacial Spasm: Essential Facts for Patients. Webpage updated 2025; English handout ©2024. Source ↩
  2. Jesuthasan A, Natalwala A, Davagnanam I, Saifee T, Zrinzo L. J Neurol. 2025;272:502. doi:10.1007/s00415-025-13220-y. Source ↩
  3. Holste K, Sahyouni R, Teton Z, Chan AY, Englot DJ, Rolston JD. World Neurosurg. 2020;139:e383–e390. doi:10.1016/j.wneu.2020.04.001. Source ↩
  4. Duarte GS et al. Cochrane Database Syst Rev. 2020;11:CD004899. doi:10.1002/14651858.CD004899.pub3. Source ↩
  5. Wang B, Wei X, Qi H, Bao X, Hu M, Ma J. BMC Neurol. 2024;24:420. doi:10.1186/s12883-024-03883-x. Source ↩